Age-related macular degeneration (AMD) is a leading cause of vision loss for which treatment options are limited. The socioeconomic benefits of prevention of AMD are enormous. While considerable observational evidence supports an association between dietary fats and AMD, the relation between specific types of fat and AMD has been unclear. Recent research has focused on the ω-3 polyunsaturated acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). The diets of industrialised nations contain higher levels of saturated fats, trans fatty acids and ω-6 fatty acids and less ω-3 fatty acids than they did in the past. This imbalance may have important implications for retinal health. Several observational studies have found that consumption of oily fish and high dietary intakes of DHA and EPA are associated with a reduced risk of developing AMD. Recent studies evaluating nutritional supplements containing ω-3 fatty acids for the treatment of AMD suggest a potential beneficial effect but further research in this area is warranted.
treatment exists for prevention or treatment of AMD.
The identification of risk factors is of major importance for understanding the origins of AMD and for establishing strategies of prevention. Current therapeutic strategies focus on delaying or halting disease progression by modifying risk factors, such as lifestyle changes, e.g. cessation of smoking, or nutritional supplements. 28, 29 Nutritional supplements are of particular interest since the nutritional quality of the diet is decreasing. Several vitamins and minerals are known to be important in eye health, with particular interest in their antioxidant efficacy, since it has been suggested that retinal damage due to oxidation may contribute towards AMD pathogenesis. 30, 31 In 2001, the Age-related eye disease study (AREDS), a large-scale randomised controlled trial, found that high doses of vitamins C and E, β-carotene and zinc significantly reduced the odds of developing advanced AMD in a high-risk group. 32 A second study It has been hypothesised that atherosclerosis of the blood vessels that supply the retina may contribute to the risk of AMD. The link between fat intake and atherosclerosis and cardiovascular disease is well established, in particular the benefits of ω-3 fatty acids. [33] [34] [35] Interest has focused on the role of dietary fatty acids in AMD. This article will examine evidence supporting the importance of ω-3 fatty acids in AMD and their possible role in its therapeutic management.
Omega-3 Fatty Acids -A General Overview
All ω-3 polyunsaturated fatty acids (PUFAs) are considered essential dietary nutrients as they cannot be synthesised by humans de novo. 36 The essential ω-3 fatty acids are the short-chain α-linolenic acid and the long-chain docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). α-linolenic acid can be found in rapeseed, soybean, flax and walnut oils, whereas DHA and EPA are found in oily fish such as mackerel, tuna, herring and salmon (see Table 1 ). 37, 38 EPA can also be synthesised from α-linolenic acid although there is minimal conversion in vivo. 39, 40 EPA is itself a precursor of DHA. The cardiovascular benefits of essential ω-3 acids have been demonstrated in clinical studies.
Treatment with ω-3 acids was found to reduce mortality and admission to hospital for cardiovascular reasons in patients with heart failure. 41 The brain and eye are highly enriched with ω-3 fatty acids, which accumulate in these tissues during early neonatal life. 42 DHA is a major structural lipid in the retina, particularly the disc membranes of photoreceptor outer segments, where it accounts for over half the total fatty acyl groups, a proportion higher than is found in any other tissue. 43 Because photoreceptor outer segments are constantly being The presence of a high concentration of DHA may affect photoreceptor function by altering membrane fluidity, permeability, thickness and lipid phase properties. 36 In humans, an optimal balance between ω-3 and ω-6 fatty acids is required for normal neuronal function, and it has been suggested that the current imbalance in the ω-6:ω-3 fatty acid ratio in the diets of industrialised nations may contribute to the observed increases in many disorders. 44 Anthropological and epidemiological studies indicate that humans evolved on a diet with a ratio of ω-6:ω-3 PUFAs of approximately 1:1, whereas in Western diets the ratio is 12:1 to 18:1. 45 Alaskan Eskimos, whose diet is rich in fish and marine mammals, have a plasma ω-6:ω-3 PUFA ratio of 3.5:1. 46 The Japan Society for Lipid Nutrition recommended a dietary ω-6:ω-3 ratio of 2:1 or less for prevention of cardiovascular disease in an elderly population. 47 A recent report has concluded that the imbalance in ω-6
and ω-3 in the Western diet is inappropriate for normal growth and development and suggests a ratio of ω-6:ω-3 PUFAs of between 1:1 and 2:1. 48 However, such a ratio is hard to achieve and the French Food Safety Agency has recommended a ratio of 5:1, which is gaining widespread acceptance.
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The Importance of Omega- The association between fat intake and development of AMD was first studied in a single-cohort study as part of the Nurses' health study and the Health professionals follow-up study, which followed 72,489 whereas fish consumption at least three times per week was associated with a reduced incidence of late ARM (OR 0.25). 53 In an extension of this study (n=3,654) to 10 years, a reduced incidence of early AMD was associated with fish consumption once a week (OR 0.69), total ω-3 fatty acid intake (OR 0.63) and consumption of one or two servings of nuts per week (OR 0.65).
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The European Eye Study EUREYE was a cross-sectional population-based study which investigated the dietary intake of DHA and EPA in 105 participants with neovascular AMD and 2,170 controls without AMD. DHA or EPA AMD signs found that intake of ω-3 fatty acids was inversely associated with AMD (OR 0.55). 56 The reduction in the risk of AMD with a higher intake of ω-3 fatty acids was seen primarily among subjects with low levels of ω-6 fatty acids. In addition, increased fish consumption reduced the risk of AMD, particularly for two or more servings per week (OR 0.64).
Age-related Eye Disease Study
Although the AREDS nutritional supplement does not contain ω-3 fatty 
Other Studies
Additional studies have examined the associations between AMD, ω-3 fatty acid intake and consumption of fish. A risk reduction in AMD was associated with the highest levels of ω-3 intake (OR 0.85, p=0.03), but not with consumption of more than two servings of fish per week, in a population of 6,734 individuals. 63 In a US study, higher intake of specific types of fat, including vegetable, monounsaturated, PUFAs and linoleic acid, rather than total fat intake, was found to be associated with a greater risk of advanced AMD. Diets high in ω-3 fatty acids and fish were associated with a lower risk of AMD only in individuals with low intake of the ω-6 fatty acid linoleic acid. 51 In a sample of 2,520 individuals, those with advanced AMD were less likely to consume fish or shellfish high in ω-3 fatty acids (OR 0.40).
There was no relationship between AMD and consumption of crab and oysters, which have high levels of zinc. 64 The third National Health and Nutrition Examination Survey (NHANES III) found associations between fat intake and AMD in a cross-sectional study. Consumption of fish more than once a week compared with once a month or less was associated with a reduced risk of early ARM (OR 1.0) and late ARM (OR 0.04, p=0.10). 
Meta-analyses
In a meta-analysis of nine studies and 88,974 participants, high dietary intake of ω-3 fatty acids was inversely associated with the risk of late AMD (OR 0.62) (see Table 2 ). 67 Moreover, fish consumption at least twice a week was associated with a reduction in both early (OR 0.76) and late (OR 0.67) AMD (see Table 2 ). benefit of the ω-3 fatty acid supplementation was observed over this short time period, no side effects were reported and a further study was considered feasible. 69 The further benefits of DHA supplementation are currently being evaluated in the NAT-2 study.
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NAT-2 is a single-centre prospective interventional randomised double-masked trial currently being conducted in France. Among its objectives is an investigation of the benefits of ω-3 supplementation for AMD. In addition, the benefits of oral supplementation with ω-3
PUFAs on the progression of AMD is being evaluated in the AREDS2 study, a multi-centre randomised placebo-controlled trial. 70 The study began in 2008, has enrolled around 4,000 participants and will run for The Taurine, omega-3 fatty acids, zinc, antioxidant, lutein (TOZAL) study treated 37 patients with dry AMD with a nutritional supplement containing EPA and DHA for six months. Of the patients receiving the nutritional supplement, 76.7 % showed an improvement or stabilisation in best corrected visual acuity. There was a statistically significant improvement in visual acuity compared with a placebo cohort constructed from the literature (p=0.045). 72 Increased median serum levels of ω-3 long chain fatty acids were also observed after six months following combined supplementation of EPA and DHA with lutein and zeaxanthin. 75 It is recommended that α-linolenic represent 0.5 % of the total energy derived from fat. 75 Based on cardiovascular considerations, an adequate intake of 250 mg/day of combined EPA + DHA is recommended in healthy adults, with an additional 100-200 mg daily for pregnant or lactating individuals to compensate for the loss of DHA to the foetus/infant. 75 In clinical studies, DHA supplementation has been found to contribute to optimal visual development in infants. [76] [77] [78] The EFSA states that "DHA contributes to the visual development of infants" and recommends an adequate intake of 100 mg/day in this age group. 75 Dietary advice for children aged 2-18 years is similar to adults, i.e. an adequate intake of ~250 mg/day combined EPA + DHA. 75 In 2010, the French Food Safety Agency 79 published its recommended intakes for fatty acids in AMD prevention: 250 mg/day of both EPA and DHA (i.e.
a total of EPA + DHA 500 mg/day).
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Conclusions and Future Developments
The majority of evidence supporting a retinoprotective role of ω-3 fatty acids is observational. These studies show that a higher level of ω-3 fatty acid intake or the regular consumption of oily fish is associated with a 30-50 % risk reduction in the occurrence or progression of AMD.
The body of evidence in support of ω-3 supplementation is growing.
Recently, a high intake of ω-3 fatty acids has been shown to negate the risk of AMD posed by genetic factors. 80 The benefits of ω-3 fatty acids for the therapeutic treatment of AMD have not been demonstrated in randomised controlled trials. However, some agencies have already stated recommendations to support dietary supplementation with ω-3 fatty acids in prevention of AMD. Moreover, the on-going prospective randomised placebo-controlled trials AREDS2 and NAT-2 should address some of these concerns.
Compared with 100 years ago, current Western diets contain higher levels of saturated fats, trans fatty acids and ω-6 fatty acids, and reduced ω-3 fatty acids. 81 Redressing this imbalance may be important for general health, not just retinal health and visual function. 48, 82 In terms of visual function, increasing the intake of DHA is likely to be more important than that of EPA because of the high levels and turnover of DHA in the retina. 36 However, both have antiangiogenic and anti-inflammatory properties, and EPA is a precursor to DHA, so an equal balance of both might be the best option. In the on-going AREDS2 study, the supplement is richer in EPA than DHA. Depending on the outcome of the AREDS2, this should be addressed in the design of future trials. Despite the fact that clinical trials of nutritional supplements are difficult to conduct and need large patient numbers, it is vital that studies are continued aimed at clarifying the benefits of ω-3 fatty acids. The EFSA has recommended an adequate intake of DHA and EPA. Equally important is that sustainable sources of ω-3 fatty acids continue to be developed and evaluated as alternatives to fish oils. 35, 83 Recently, it has been shown that combinations of nutrients from food including vitamins, antioxidants and ω-3 are more strongly associated with a lower risk of AMD than single nutrients.
